Member Info for Cashintime

I think the acceptance or invitation by the ASH foundation to give a presentation on their Polb 001 study speaks for itself. They would be intolerant to any sort of snake oil salesman presentation and would only deal in medically proven up product with correct clinical data, patents acceptance backing it up. This is the only way the science world can work.

It is the most prestigious hematology conference get together with 25,000 industry specialists in attendance every year. We are further proving up our product and looking for the blockbuster deal it deserves. Things will be different here by years end I believe as there is a lot stirring in the background.

The industry will sit up and take notice of Polb 001 now as we proceed to prove up our blockbuster product. IPO price should be seen again shortly.

Https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-polb/poolbeg-pharma-shares/news/uk-penny-stocks-to-watch-in-november-2024

We know that we are doing the oral encapsulation trial before years end so news on that front should be arriving soon. We were said to be turning the corner at the start of the year on our quest to become cash generating and I think it is in the wheels of motion. With many shots on goal and our expectations for Nasdaq listing I feel that we are dotting the I's and crossing the T's on a deal as we speak.

Nice tick up. Could we get back to IPO in the short term I think so as news will surely come in November before the Christmas wind down.

He said it in a presentation recently organised by the Telegram group which wasn't recorded but many heard.

JS is over in Stockholm at the moment at Bio Europe until 6th November. I hope he has to beat them away as they come towards him shaking their signing pens in the air.

Good to see the slight momentum continuing this morning in anticipation of the groundbreaking news that we are expecting. I'm looking forward to a very possible upward projectury on the receipt of it. Let's hope that we are not disappointed but I don't think so. CF said we will all be happy at Christmas.

We know that something big is going to break this month that will give us the ability to reverse onto Nasdaq. Will we be the ones with the cash and partner up with a company who has revenue generating assets or are we bringing the products to a cash rich company is the question.

10 weeks left to Christmas and they are hardly going to leave it that long so a deal must already been agreed in principle. We must have some deal to bring to the table to our Nasdaq listed company .

I don't know Spuddy but it was only put up on YouTube yesterday. It is meant I think as a message to investors to maintain confidence in Poolbeg as we await a deal. Alot going on in the background and they want to keep their cards close to their chest.

It would be preferable to be at a higher market cap at the time of reversal to maximise our allocations at a new shareprice I would think.

Hi Spuddy, I think maybe reverse into that Nasdaq company that we are working at carrying out the oral encapsulation trial Anabio product with.

Only a guess but since we can't do it alone without a blockbuster deal it is quiet possible.

"Poolbeg will go on Nasdaq later on this year"

Clearly stated by Cathal Friel.

Https://youtu.be/dMRAbhrJdN0?si=dnpSQ9uw1WeWhPN8

Poolbeg from 11mins in

Hope to see some news this week to give us all a bit of confidence of a deal closing by years end. We have to presume that the silence is due to a deal being finalised and management don't want to jinx it at the twilight hour. I have to admit I was a lot more relaxed when we were floating at 20% above IPO price. Michael Kelly must have reason to be confident of a deal that will propel the market cap of this company. If we can secure the first cash injection that we aspire to have it will leave us in the great position with many irons in the fire and the exposure to start a domino effect of deals. We have a fine team that will bring this company to the planned position that our model is based on. I feel a reverse into Nasdaq is being worked on and as CF has said we should all be happy by Christmas. We await patiently.

You are obviously looking for a cheap buy in price for a 10,15 or 20% trade and no doubt all your negativity here is to try and make small amounts of money. If you focused your energy somewhere else with such vigor you may find that life just may get easier for you as you reap the fruits of honesty hard work . You are not invested here so why are you here , but then there is always one to take up the role you play. Winners and losers. Which are you.

There is a great incentive for the management to get a deal over the line as they will be rewarded handsomely with free shares once the share price stays above 17.945p for 14 days.

Dave Allmond has 7.7+m options a lot of them will to profit around £1m

I hope they are focused and I presume that there is no time for slackers here.

Https://www.cnbc.com/2024/09/16/radiopharmaceuticals-race-heats-up-as-drugmakers-chase-novartis.html

I wonder will any of the deep pockets of big Pharma come out way.

Is there any of our AI identified targets in this field. We are applying for IP for the cream of the crop I presume before it is made public.

Is it not 3 months after the period for 6 month results. That would bring us to end of September.